Grifols, S.A. (NASDAQ:GRFS) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $24.00.
Several research analysts recently weighed in on GRFS shares. Bank of America Corporation started coverage on Grifols, in a research note on Thursday, April 6th. They set a “buy” rating for the company. HSBC Holdings plc cut Grifols, from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Zacks Investment Research cut Grifols, from a “buy” rating to a “hold” rating in a research note on Friday, May 5th. BidaskClub cut Grifols, from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Goldman Sachs Group, Inc. (The) downgraded Grifols, from a “buy” rating to a “neutral” rating in a report on Friday, June 30th.
Grifols, (NASDAQ:GRFS) traded up 2.39% on Tuesday, hitting $20.95. The stock had a trading volume of 409,597 shares. The stock has a 50-day moving average of $21.04 and a 200-day moving average of $19.52. Grifols, has a one year low of $14.27 and a one year high of $22.83. The company has a market cap of $28.07 billion, a PE ratio of 44.01 and a beta of 0.98.
A number of large investors have recently made changes to their positions in the company. Huntington National Bank increased its stake in Grifols, by 1.2% in the first quarter. Huntington National Bank now owns 6,704 shares of the biotechnology company’s stock worth $127,000 after buying an additional 77 shares during the period. Financial Counselors Inc. increased its stake in Grifols, by 0.8% in the first quarter. Financial Counselors Inc. now owns 16,327 shares of the biotechnology company’s stock worth $308,000 after buying an additional 131 shares during the period. Comerica Bank increased its stake in Grifols, by 1.0% in the first quarter. Comerica Bank now owns 18,817 shares of the biotechnology company’s stock worth $398,000 after buying an additional 185 shares during the period. Bank of Montreal Can increased its stake in Grifols, by 0.7% in the second quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after buying an additional 457 shares during the period. Finally, Stifel Financial Corp increased its stake in Grifols, by 4.3% in the first quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after buying an additional 476 shares during the period. 22.51% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Analysts Set Grifols, S.A. (GRFS) Price Target at $24.00” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2017/07/31/analysts-set-grifols-s-a-grfs-price-target-at-24-00-updated.html.
Grifols, Company Profile
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.
